• Discover Astex
    • Our Mission & Values
    • Our Leadership Team
    • Research Fellows
    • Our History
    • Corporate Social Responsibility
    • Environmental Sustainability
  • R&D
    • Clinical Pipeline
    • Pyramid™ Discovery Platform
    • Oncology and CNS Discovery
    • Sustaining Innovation Postdocs
  • Partnering
  • Our People & Culture
    • Career Opportunities
  • Media
    • Press Releases
    • Conferences & Meetings
    • Presentations & Publications
    • Interactive Scientific Resources
      • Interactive Software
    • Astex in the News
  • Contact
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
You are here: Home1 / 20042 / SuperGen Reports Results from Dacogen™ Phase III Study in Myelodysplastic S...

SuperGen Reports Results from Dacogen™ Phase III Study in Myelodysplastic Syndromes (MDS)

31 March 2004/in 2004, News

SuperGen Reports Results from Dacogen™ Phase III Study in Myelodysplastic Syndromes (MDS)

https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg 0 0 webadmin https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg webadmin2004-03-31 14:33:282016-11-28 14:33:49SuperGen Reports Results from Dacogen™ Phase III Study in Myelodysplastic Syndromes (MDS)

© Astex Pharmaceuticals
All rights reserved

astex

Useful links

  • Home
  • Sitemap
  • Privacy Policy
  • Terms of Use
  • Legal
  • LinkedIn

Member of the Otsuka Group

A selection of photos on this website
is courtesy of Valerio Berdini

Link to: SuperGen’s New Drug Application for Orathecin™ (rubitecan) Capsules Accepted by FDA for Filing Link to: SuperGen’s New Drug Application for Orathecin™ (rubitecan) Capsules Accepted by FDA for Filing SuperGen’s New Drug Application for Orathecin™ (rubitecan) Capsules... Link to: Astex achieves second milestone in Alzheimer’s drug discovery collaboration with AstraZeneca Link to: Astex achieves second milestone in Alzheimer’s drug discovery collaboration with AstraZeneca Astex achieves second milestone in Alzheimer’s drug discovery collaboration...
Scroll to top Scroll to top Scroll to top